open access
Case of skin basal cell carcinoma — how to treat, when surgeon no longer can?
Affiliations- WWSz im. M.Kopernika w Łodzi, Łódź
- Uniwersytet Medyczny w Łodzi
open access
Abstract
Basal cell carcinoma (BCC) is rarely metastatic skin cancer, that represents 80% of all non-melanoma skin cancers (NMSC). Typically, BCC lesions are mainly located on sun exposed skin areas such as face. Although BCC is very rarely metastasis it could affect and damage neighboring tissues causing significant cosmetic defects. Surgical operation that enables tumor resection with full histological diagnosis should be considered as a first-line treatment. Other therapies include ablation techniques and no surgical procedures such as local pharmacotherapy, photodynamic therapy, radiotherapy and chemiotherapy. It is important to take into account all factors such as tumor features, localization, acceptable aesthetic effect and ability to keep function of affected skin areas. We describe a case of a 70-old year man patient with a diagnosis of locally malignant BCC, in which the use of surgical excision and radiation therapy did not result in a long-term clinical benefit.
Abstract
Basal cell carcinoma (BCC) is rarely metastatic skin cancer, that represents 80% of all non-melanoma skin cancers (NMSC). Typically, BCC lesions are mainly located on sun exposed skin areas such as face. Although BCC is very rarely metastasis it could affect and damage neighboring tissues causing significant cosmetic defects. Surgical operation that enables tumor resection with full histological diagnosis should be considered as a first-line treatment. Other therapies include ablation techniques and no surgical procedures such as local pharmacotherapy, photodynamic therapy, radiotherapy and chemiotherapy. It is important to take into account all factors such as tumor features, localization, acceptable aesthetic effect and ability to keep function of affected skin areas. We describe a case of a 70-old year man patient with a diagnosis of locally malignant BCC, in which the use of surgical excision and radiation therapy did not result in a long-term clinical benefit.
Keywords
basal cell carcinoma, locally malignant, vismodegib
About this articleTitle
Case of skin basal cell carcinoma — how to treat, when surgeon no longer can?
Journal
Issue
Article type
Case report
Pages
58-62
Published online
2017-08-21
Page views
4771
Article views/downloads
91820
Bibliographic record
Forum Dermatologicum 2017;3(2):58-62.
Keywords
basal cell carcinoma
locally malignant
vismodegib
Authors
Magdalena Anna Ciążyńska
Paulina Szczęsna
Joanna Narbutt
Aleksandra Lesiak
References (31)- Pabiańczyk R, Cieślik K, Tuleja T. Metody leczenia raka podstawnokomórkowego skóry. Chirurgia Polska. 2011; 13(1): 48–58.
- Nejc D, Piekarski J, Pasz-Walczak G, et al. Rak podstawnokomórkowy skóry — młody wiek chorych przyczyną wątpliwości diagnostycznych. Onkol Pol. 2002; 5: 179–181.
- von Domarus H, Stevens PJ. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol. 1984; 10(6): 1043–1060.
- Snow SN, Sahl W, Lo JS, et al. Metastatic basal cell carcinoma. Report of five cases. Cancer. 1994; 73(2): 328–335.
- Tilli CM, Van Steensel MAM, Krekels GAM, et al. Molecular aetiology and pathogenesis of basal cell carcinoma. Br J Dermatol. 2005; 152(6): 1108–1124.
- Riefenberger J, Ruzicka T. Rak podstawnokomórkowy (BCC). In: Giliński W. ed. Dermatologia Braun-Falco t.3. Czelej, Lublin 2011: 1372–1380.
- Jabłońska S, Najewski S. Choroby skóry i choroby przenoszone drogą płciową. PZWL, Warszawa 2005: 400–403.
- Jochymski C, Lesiak A, Słowik-Rylska M, et al. Ekspresja białka Ki-67 i β-kateniny w powierzchownej i guzkowej odmianie raka podstawnokomórkowego. Postępy Dermatologii i Alergologii. 2008; 25(5): 269–275.
- Kapuśniak V, Dzimira S. Rak podstawnokomórkowy. Medycyna Weterynaryjna. 2006; 62(3): 270–273.
- Kerkela E, Saarialho-Kere U. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Experimental Dermatology. 2003; 12(2): 109–125.
- Daniel L, Leoniewski-Kmak K. Leczenie długotrwale rozwijającego się raka podstawnokomórkowego skóry, niszczącego połowę twarzy – opis przypadku. Współczesna Onkologia. 2005(9): 440–442.
- Charakterystyka produktu leczniczego Erivedge®, ostatnia aktualizacja w dniu 16 lutego 2015 r. (aktualna). http://www.ema.europa.eLi/ema/index.isp?curl=paaes/medicines/human/mediciries/0Q26Q2/human (9.06.2017).
- Hossfeld DK, Sherman CD, Love RR. Podręcznik onkologii klinicznej. PWN,, Warszawa—Kraków 1994: 202–204.
- Malone JP, Fedok FG, Belchis DA, et al. Basal cell carcinoma metastatic to the parotid: report of a new case and review of the literature. Ear Nose Throat J. 2000; 79(7): 511-515 518-519.
- Williams LS, Mancuso AA, Mendenhall WM. Perineural spread of cutaneous squamous and basal cell carcinoma: CT and MR detection and its impact on patient management and prognosis. Int J Radiat Oncol Biol Phys. 2001; 49(4): 1061–1069.
- Leibovitch I, McNab A, Sullivan T, et al. Orbital invasion by periocular basal cell carcinoma. Ophthalmology. 2005; 112(4): 717–723.
- Meads SB, Greenway HT. Basal cell carcinoma associated with orbital invasion: clinical features and treatment options. Dermatol Surg. 2006; 32(3): 442–446.
- Farley RL, Manolidis S, Ratner D. Aggressive basal cell carcinoma with invasion of the parotid gland, facial nerve, and temporal bone. Dermatol Surg. 2006; 32(2): 307–15; discussion 315.
- Lear JT, Corner C, Dziewulski P, et al. Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective. Br J Cancer. 2014; 111(8): 1476–1481.
- Bath FJ. Interventions for basal cell carcinoma of the skin. Cochrane Rev Abstract. ; 2005.
- Breuninger H, Dietz K. Prediction of subclinical tumor infiltration in basal cell carcinoma. J Dermatol Surg Oncol. 1991; 17(7): 574–578.
- Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol. 1987; 123(3): 340–344.
- Kimyai-Asadi A, Alam M, Goldberg LH, et al. Efficacy of narrow-margin excision of well-demarcated primary facial basal cell carcinomas. J Am Acad Dermatol. 2005; 53(3): 464–468.
- Telfer NR, Colver GB, Morton CA, et al. British Association of Dermatologists. Guidelines for the management of basal cell carcinoma. Br J Dermatol. 2008; 159(1): 35–48.
- Wilder RB, Margolis LW. Skin Cancer. Texbook of Radiation Onkology. Leibel S. A. Philips TL, WB Sanders Company Philadelphia 1st ed. ; 1998: 1165–79.
- Kian An, Morrison WH, Gorden AS. Cutaneous carcinoma and melanoma in Clinical Radiation Oncology. Gunderson LL, Tepper JE. 1st ed. Churchill Livingstone, Philadelphia : 563–576.
- Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012; 366(23): 2171–2179.
- Sekulic A, Migden MR, Basset-Seguin N, et al. Long term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): Final update (30 months) of pivotal ERIVANCE BCC study. J Clin Oncol. 2014; 32(suppl): 9013.
- Ridky TW, Cotsarelis G. Vismodegib resistance in basal cell carcinoma: not a smooth fit. Cancer Cell. 2015; 27(3): 315–316.
- Pricl S, Cortelazzi B, Dal Col V, et al. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol. 2015; 9(2): 389–397.
- Charakterystyka produktu leczniczego sonidegib – odomzo . http://www.ema.europa.eu/docs/pl_PL/document_library/EPAR_-_Summary_for_the_public/human/002839/WC500192969.pdf; (9.06.2017).
